AstraZeneca and Ionis drug for rare disease achieves positive trial data

2022.06.21 11:06

FILE PHOTO: The logo for AstraZeneca is seen outside its North America headquarters in Wilmington, Delaware, U.S., March 22, 2021. REUTERS/Rachel Wisniewski/File Photo

LONDON (Reuters) – An interim analysis of AstraZeneca (NASDAQ:AZN) and partner Ionis Pharmaceuticals (NASDAQ:IONS)’ eplontersen showed the experimental drug met the main goals in a late-stage trial in patients with a rare, fatal disease, the Anglo-Swedish drugmaker said on Tuesday.

Based on the results, the companies plan to file an application to market the therapy in the United States later this year in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN).

Source